Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 957-958

  Houot, Roch ^a   Kohrt, Holbrook ^b   Levy, Ron ^c  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

ADCC; Antibody; CD137; NK cell; Synergy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CD137 ANTIBODY; CD137 ANTIGEN; CD20 ANTIBODY; CD40 AGONIST; CD47 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 21; KIR ANTIBODY; LENALIDOMIDE; MICRORNA 155; MONOCLONAL ANTIBODY; RITUXIMAB; THALIDOMIDE; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL ACTIVATION; CELL STIMULATION; DEGRANULATION; DRUG POTENTIATION; HUMAN; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

EID: 84886944363     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19974     Document Type: Article

References (10)

1. Clynes RA, Towers TL, Presta LG, Ravetch J V. Inhibitory Fc receptors modulate in vivo cytotoxic-ity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
2. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957.
3. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with fol-licular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10.1200/JCO.2003.05.013.
4. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205.
5. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945.
6. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226.
7. Melero I, Murillo O, Dubrot J, Hervás-Stubbs S, Perez-Gracia JL. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008; 29:383-90; PMID:18599129; http://dx.doi.org/10.1016/j.tips.2008.05.005.
8. Houot R, Kohrt H, Goldstein MJ, Levy R. Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev 2011; 30:97-109; PMID:21271352; http://dx.doi.org/10.1007/s10555-011-9274-3.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
10. Robert C, Thomas L, Bondarenko I, O'Day S, MD JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621.